GW 9508 – 50 mg

Brand:
Cayman
CAS:
885101-89-3
Storage:
-20
UN-No:
Non-Hazardous - /

GW 9508 is a small-molecule agonist of GPR40/FFA1 (EC50 = 47.8 nM for calcium mobilization in HEK293 cells).{14194} It is selective for GPR40/FFA1 over GPR120/FFA4 (EC50 = 3,467 nM), as well as GPR43/FFA2 and GPR41/FFA3 (EC50s = >50 µM).{14194} GW 9508 potentiates glucose-stimulated and potassium chloride-mediated insulin secretion in MIN6 pancreatic β-cells but does not affect glucose-stimulated insulin secretion in primary rat or mouse islet cells.{14194} It increases phosphorylation of AMP-activated protein kinase (AMPK) and acyl-CoA carboxylase (ACC), indicating AMPK and ACC activation, and decreases hepatic lipid accumulation in a mouse model of high-cholesterol diet-induced hepatic steatosis when administered at a dose of 100 mg/kg per day for three days.{43588}  

 

Available on backorder

SKU: 10008907 - 50 mg Category:

Description

An agonist of GPR40/FFA1 (EC50 = 47.8 nM); selective for GPR40/FFA1 over GPR120/FFA4 (EC50 = 3,467 nM), as well as GPR43/FFA2 and GPR41/FFA3 (EC50s = >50 µM); potentiates glucose-stimulated and potassium chloride-mediated insulin secretion in MIN6 cells; activates AMPK-ACC signaling; decreases hepatic lipid accumulation in a mouse model of high-cholesterol diet-induced hepatic steatosis at 100 mg/kg per day for three days


Formal name: 4-[[(3-phenoxyphenyl)methyl]amino]-benzenepropanoic acid

Synonyms: 

Molecular weight: 347.4

CAS: 885101-89-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Lipid Biochemistry|Acyl-CoAs||Research Area|Lipid Biochemistry|Fatty Acids